Plain-English translation of NCT07181122 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is watching how men with advanced, hormone-sensitive prostate cancer do over time when they receive treatment with androgen receptor pathway inhibitors (medications like abiraterone acetate, apalutamide, enzalutamide, or darolutamide) combined with standard hormone therapy. Researchers want to understand how this medication affects not just the cancer, but also your thinking, energy levels, mood, sleep quality, and ability to do daily activities.
While this medication has been shown to help control advanced prostate cancer and improve survival, doctors don't fully understand how it affects patients' thinking ability, tiredness, mood, and sleep in real-world life. This study will fill that gap by carefully tracking these important parts of quality of life.
You likely qualify if…
You likely don't qualify if…
You will visit the hospital or clinic three times over six months: at the start, after 3 months, and after 6 months. At each visit, you'll answer questionnaires about your thinking ability, tiredness, mood, and sleep quality. The study will also record routine blood tests and any side effects from the medication. You'll continue your regular cancer treatment as planned — the study is simply watching and tracking how you're doing.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Turkey (Türkiye)